ARGENX SE (ARGX) WON ITS PHASE 3 MYOSITIS TRIAL. HOW MUCH DOES THE SUBGROUP MISS MATTER? - YAHOO

Phase 3 win is pivotal, but subgroup miss raises efficacy questions for investors.